FindTrial
Sign In

A novel risk-scoring system conducing to chemotherapy decision for resectable pancreatic ductal adenocarcinoma: A retrospective cohort study

A novel risk-scoring system conducing to chemotherapy decision for resectable pancreatic ductal adenocarcinoma: A retrospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000038626
Enrollment
Unknown
Registered
2020-09-26
Start date
2020-09-26
Completion date
Unknown
Last updated
2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

resectable PDAC:chemotherapy

Sponsors

Xiangya Hospital, Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: The target population was limited to the resectable PDAC patients from the SEER database(ICD-O-3: 8140, 8141, 8144, 8160, 8170, 8210, 8211, 8255, 8260, 8261, 8263, 8290, 8310, 8323, 8342, 8350, 8430; RX Summ--Surg Prim Site (1998+): 10-90) diagnosed in the periods of 2004-2015.

Exclusion criteria

Exclusion criteria: Survival months is 0-3 (n=923); TNM stage is UNK Stage (n=268); CS extension is unknown (n=36); code of CS tumor size is 0 (n=1).

Design outcomes

Primary

MeasureTime frame
overall survival;—

Countries

China

Contacts

Public ContactFengbo Tan

Xiangya Hospital, Central South University

fengbotan@csu.edu.cn+86 18569498707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026